A Phase Ib, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BDB-001 Injection in Patients With Novel Coronavirus (2019-nCoV) Infection
Latest Information Update: 23 May 2024
At a glance
- Drugs BDB 001 Beijing Defengrei Biotechnology (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Staidson Beijing BioPharmaceuticals
- 20 May 2024 Status changed from completed to discontinued. ( Due to the COVID-19 epidemic situation, the sponsor has decided to terminate the project.)
- 18 Oct 2021 New trial record